Sanofi and GSK Present Promising Data for Bivalent COVID-19 Vaccine

Sanofi and GSK announced positive data from a late-stage study of their investigational bivalent COVID-19 vaccine candidate against the original SARS-CoV-2 virus and the Beta variant.

In the phase 3 trial that enrolled more than 13,000 participants aged 18 years and older, the vaccine had an efficacy rate of 64.7 percent against symptomatic COVID-19 and a 72 percent efficacy rate in preventing symptomatic Omicron cases, the companies said.

The immunogenicity data support the use of the adjuvanted recombinant protein vaccine against variants such as Omicron, said Thomas Triomphe, Sanofi’s executive vice president for vaccines.